Ruti Aga's Six-Year Ban: Two Years for the Substance, Four for a Prescription That Never Existed

The investigators reached the clinic named on Ruti Aga's prescription. There was no clinic. The "doctor" who had signed it turned out to be a family member with no medical registration, who explained that he had used an old prescription pad from a former workplace — and that former workplace flatly denied ever owning such a pad. Three separate checks, three separate answers, one conclusion: the paper was false.

This is the point where the story stops being sport and becomes a document audit. The Athletics Integrity Unit's ruling against the 32-year-old Ethiopian marathoner is a six-year ban counted from 10 September, the same date her provisional suspension began. Six years sounds like the unearthing of a doping network. Break the sum apart and the picture inverts: two years for the substance, four years for the paper manufactured to hide it. The heaviest instalment of the sentence was collected not by pharmacology but by stationery.

Start with the record, because it sets the scale. Second at Berlin 2026 in 2:18:34. Victory at Tokyo 2026 in 2:20:40. Three runner-up finishes at World Marathon Majors. This is the tier where an athlete is paid not to run but to be invited — appearance fees, the bridge between the Majors and the label-race circuit.

Then came March. A half marathon in China, won, and an in-competition sample. The sample contained methylprednisolone. A technical correction is necessary here, because early reports called it a "prohibited steroid," which is wrong. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9, not S1. And S9 is prohibited in-competition only, and only by injection, oral or rectal route. Which means a therapeutic knee injection given out of competition is entirely legal. It becomes a violation only if residues are present in-competition.

That distinction is the hinge of the entire case, and the mainstream reporting missed it. Intra-articular methylprednisolone for knee synovitis is ordinary sports-medicine practice in distance runners. The explanation she offered was not medically absurd. That is the bitter irony: the defence that could actually have worked was the one she cut away with forged paper.

Now the arithmetic. Two years for presence — a prohibited substance in the body. Four years for tampering — an attempt to mislead the investigation. Six in total. Under the 2026 WADA Code this is standard: four years is the default tampering sanction. The real question is not why four; it is why the presence sanction stopped at two.

Consider the defence that existed. Real medical records, a real clinic register, documentation of the injection's date and route, and the argument becomes straightforward: legitimate treatment before the competition, with the washout period miscalculated. That sits in the no-significant-fault band, the sanction falls well below two years, and no tampering charge arises at all. In the best case — a proper TUE and correct washout timing — there is no case whatsoever.

Instead, she manufactured a prescription. And here an odd paradox appears: forged documentation is itself circumstantial evidence of intent to conceal, yet it did not aggravate the presence sanction — the panel treated it as a separate tampering count. The ledger never closes; it only changes hands.

One thing the AIU statement leaves unwritten but the decision implies: the March race result and its prize money will almost certainly be annulled, along with any ranking points accrued after that date. Standard AIU practice is automatic disqualification of the competition where the sample was collected. The 2026 Tokyo title, however, stands — there is no finding of earlier use, so that line in the record book is not erased. I went looking for a number and found a system wearing it: the sanction's scope is bounded by the substance, not by the career.

The true root cause is the knee, and it is a systemic question rather than an individual one. An injured marathoner faces pressure to protect appearance-fee income, glucocorticoids are the cheapest and most available tool for masking pain, and the surrounding medical network is informal. An athlete without a credentialed team physician does not walk the TUE route — she walks toward an old pad. This was not a filing error; it was the signature of a career running without a certified team doctor.

I have kept a file on every foreign expert the Indian federation has hired since 2026, and every Asian road-race split sheet since Kalinga 2026. A pattern runs through them: where the team-doctor post is written into a contract, prescriptions never become disputed; where the post exists only verbally, paper gets manufactured. The question here is administrative before it is ethical.

There is an economic layer too. China's label road races are the income tier between Majors for East African marathoners — good appearance fees, thin competition, low risk. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. The race the athlete reads as income, the agency reads as a sample collection site.

The counter-case deserves airtime, because it is absent from the AIU release. Six years landed on a substance with no proven endurance benefit. Methylprednisolone reduces pain and swelling; it does not raise haemoglobin or build muscle. Those who will cite this as proof of a rigorous AIU and those who will call it disproportionate enforcement against African road runners are both stopped by one figure: two years were for the substance, four for the paper. If there is severity here, it sits on document verification, not on pharmacology.

A second inversion: the competitive landscape is untouched. Ethiopia's women's marathon has a sub-2:16 cohort; a 2:18–2:20 runner is not automatically selectable. Aga's three Major second places were commercial-tier results, never converted into championship medals. One 32-year-old stepping out for six years does not alter a single line of national selection arithmetic. What shifts is the integrity regime, not the medal table.

Third, the shape of the investigation. The four-year tampering charge came from an interview as much as from a document — from statements made under questioning. Language and interpretation conditions in AIU interviews with East African athletes have been a recurring point of contention. That does not reduce the sentence, but part of it belongs to a failure of communication, not solely to deceit.

Fourth, and least noticed: no statement from the Ethiopian federation is on record. Only the AIU spoke. In a country whose national identity is built on the marathon, silence at national level over a former Major champion's six-year ban is itself a document. Two dates, one athlete, and the full arithmetic in between — with one box left empty that was never the agency's alone to fill.

Six years from 10 September, imposed at 32, means a return at 38. Commercially, that is a lifetime ban, and the lifetime outcome was delivered not by the substance but by the prescription. Somewhere between the stopwatch and the spreadsheet a career is decided; here that place was the address of a clinic that never existed.

The forward question is not who gets named next. The AIU's investigative frontier has moved from detection to verification, and more cases will come out of training clusters served by the same informal medical networks — because a pad that gets forged is a product of a system, not of one athlete. The real question is whether the next knee injection arrives with a genuine receipt or an old pad. A stadium remembers what a press release forgets — and Tokyo 2026's 2:20:40 still stands in the record book, even as every document after it came under scrutiny.